Egg allergy trials halted by Aimmune; Atlas closes its 13th fund for $450M
A Phase II trial for Aimmune’s drug to treat children and young adults with egg allergies has been terminated.
The trial was terminated on Feb …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
